Patient and transplant characteristics
| . | All n (%) . | BOS n (%) . | cGVHD skin n (%) . | No cGVHD n (%) . | P . |
|---|---|---|---|---|---|
| Number of patients | 136 | 46 | 49 | 41 | |
| Median age in years (range) | 41 (19-72) | 37 (19-63) | 43 (21-72) | 46 (20-65) | |
| Gender | |||||
| Male | 62 (46) | 24 (52) | 20 (41) | 18 (44) | |
| Female | 74 (54) | 22 (48) | 29 (59) | 23 (56) | |
| Diagnosis | |||||
| Acute leukemia | 99 (71) | 34 (74) | 36 (75) | 29 (70.7) | |
| Chronic myeloid leukemia | 6 (4) | 3 (6.5) | 3 (6) | 0 | |
| Malignant lymphoma | 16 (12) | 7 (15.2) | 4 (8) | 5 (12.2) | |
| Other† | 15 (11) | 2 (4.3) | 6 (12) | 7 (17.1) | |
| Disease status at HCT | |||||
| Standard risk‡ | 61 (45) | 25 (54) | 15 (31)** | 21 (51)** | *.054 |
| High risk | 75 (55) | 21 (46) | 34 (69) | 20 (49) | |
| Conditioning regimens | |||||
| Myeloablative | 88 (65) | 32 (70)* | 38 (78) | 18 (44)* | *.018 |
| Reduced intensity | 48 (35) | 14 (30) | 11 (25)** | 23 (56)** | **.002 |
| Stem cell donors | |||||
| Related | 34 (25) | 11 (24) | 13 (27) | 10 (24) | |
| Unrelated | 102 (75) | 35 (76) | 36 (73) | 31 (76) | |
| HLA-identical | 115 (84) | 36 (78)* | 40 (82) | 39 (95)* | *.02 |
| HLA-mismatch | 21 (16) | 10 (22) | 9 (18) | 2 (5) | |
| Stem cell source | |||||
| Bone marrow | 6 (4) | 2 (4) | 3 (6) | 1 (2) | |
| PB | 128 (94) | 43 (93) | 45 (92) | 40 (98) | |
| Umbilical cord | 2 (1) | 1 (2.2) | 1 (2) | 0 | |
| Median number of CD34+ cells ×106/kg transplanted (range) | 6.5 (0.9-9.9) | 6.5 (0.9-9.5) | 6.5 (2.8-9.9) | 6.5 (1.4-9.9) | |
| Prophylaxis of acute GVHD | |||||
| CSA | 3 (2) | 1 (2) | 1 (2) | 1 (2) | |
| CSA + MTX | 94 (69) | 39 (85)* | 37 (76) | 18 (44)* | *.0001 |
| CSA + MMF | 39 (29) | 6 (13) | 11 (22)** | 22 (54)** | **.003 |
| . | All n (%) . | BOS n (%) . | cGVHD skin n (%) . | No cGVHD n (%) . | P . |
|---|---|---|---|---|---|
| Number of patients | 136 | 46 | 49 | 41 | |
| Median age in years (range) | 41 (19-72) | 37 (19-63) | 43 (21-72) | 46 (20-65) | |
| Gender | |||||
| Male | 62 (46) | 24 (52) | 20 (41) | 18 (44) | |
| Female | 74 (54) | 22 (48) | 29 (59) | 23 (56) | |
| Diagnosis | |||||
| Acute leukemia | 99 (71) | 34 (74) | 36 (75) | 29 (70.7) | |
| Chronic myeloid leukemia | 6 (4) | 3 (6.5) | 3 (6) | 0 | |
| Malignant lymphoma | 16 (12) | 7 (15.2) | 4 (8) | 5 (12.2) | |
| Other† | 15 (11) | 2 (4.3) | 6 (12) | 7 (17.1) | |
| Disease status at HCT | |||||
| Standard risk‡ | 61 (45) | 25 (54) | 15 (31)** | 21 (51)** | *.054 |
| High risk | 75 (55) | 21 (46) | 34 (69) | 20 (49) | |
| Conditioning regimens | |||||
| Myeloablative | 88 (65) | 32 (70)* | 38 (78) | 18 (44)* | *.018 |
| Reduced intensity | 48 (35) | 14 (30) | 11 (25)** | 23 (56)** | **.002 |
| Stem cell donors | |||||
| Related | 34 (25) | 11 (24) | 13 (27) | 10 (24) | |
| Unrelated | 102 (75) | 35 (76) | 36 (73) | 31 (76) | |
| HLA-identical | 115 (84) | 36 (78)* | 40 (82) | 39 (95)* | *.02 |
| HLA-mismatch | 21 (16) | 10 (22) | 9 (18) | 2 (5) | |
| Stem cell source | |||||
| Bone marrow | 6 (4) | 2 (4) | 3 (6) | 1 (2) | |
| PB | 128 (94) | 43 (93) | 45 (92) | 40 (98) | |
| Umbilical cord | 2 (1) | 1 (2.2) | 1 (2) | 0 | |
| Median number of CD34+ cells ×106/kg transplanted (range) | 6.5 (0.9-9.9) | 6.5 (0.9-9.5) | 6.5 (2.8-9.9) | 6.5 (1.4-9.9) | |
| Prophylaxis of acute GVHD | |||||
| CSA | 3 (2) | 1 (2) | 1 (2) | 1 (2) | |
| CSA + MTX | 94 (69) | 39 (85)* | 37 (76) | 18 (44)* | *.0001 |
| CSA + MMF | 39 (29) | 6 (13) | 11 (22)** | 22 (54)** | **.003 |
CSA, cyclosporine A; MMF, mycophenolate mofetil.
Indicates significant difference between the BOS cohort and the no-cGVHD cohort.
Indicates significant difference between the cGVHD skin cohort and the no-cGVHD cohort.
Other diagnoses included myelodysplastic syndrome and chronic lymphocytic leukemia.
‡Standard risk was defined as acute leukemia in first or second complete remission or chronic myeloid leukemia in first chronic phase. High risk disease included myelodysplastic syndrome and advanced stage of acute and chronic leukemia.